High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds

NEW YORK – By measuring the functional MAPK activity of different RAS mutations, researchers have developed a method they believe could help identify patients with RAS-mutated cancers likely to benefit from MEK inhibitors like trametinib (Novartis’ Mekinist).

To the publication →